tralokinumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Monoclonal antibody therapies have a growing role in treating refractory airway disease.
Abstract not available. Disclosures: Study sponsored by LEO Pharma Copyright 2018 SKIN
Interleukin (IL)‐13 is involved in the pathogenesis of some types of asthma. Tralokinumab is a human immunoglobulin G4 monoclonal…
Abstract not available. Disclosures: Study sponsored by LEO Pharma. Copyright 2018 SKIN
RATIONALE: We sought biomarkers to identify asthma patients (pts) likely to benefit from tralokinumab, an anti–IL-13 IgG4…
Contrary to a decade ago, clinical development in ulcerative colitis (UC) has become highly active with multiple promising…
Rationale: Serum periostin has been proposed as a systemic biomarker of IL-13 pathway activation in the lung. We developed an…
Introduction: Asthma is a chronic inflammatory disease of the airways mainly related to allergen exposure, in which various…
Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and…